FDA-cleared profile

Brainomix 360 e-ASPECTS

Brainomix Limited · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Brainomix 360 e-ASPECTS registers adult non-contrast brain CT, segments ASPECTS regions, and provides an editable ASPECTS score with highlighted regions and voxel contribution views to assist trained clinicians evaluating suspected ischemic stroke within 24 hours of last known well.

Clinical role
Automated ASPECTS registration, region segmentation, and decision-support visualization for clinician review of suspected ischemic stroke; it is not a primary diagnostic interpretation or mobile diagnostic result.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: The tool is not a primary interpretation, does not provide a mobile diagnostic result, and requires clinician review and editing. The FDA intended population excludes hemorrhagic transformation or hematoma and is tied to adult patients within 24 hours of last known well; the validation scanner scope was limited and later versions or other scanners require confirmation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Brainomix 360 e-ASPECTS registers adult non-contrast brain CT, segments ASPECTS regions, and provides an editable ASPECTS score with highlighted regions and voxel contribution views to assist trained clinicians evaluating suspected ischemic stroke within 24 hours of last known well.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Adult non-contrast brain CT DICOM images for suspected acute ischemic stroke within 24 hours of last known well; the FDA validation was tied to specified Siemens Somatom Definition scanner configurations.
  • Who uses it?Intended users: Trained clinicians evaluating suspected acute ischemic stroke; the output is assistive, editable, and not a replacement for primary image interpretation or clinical judgment.
  • What does the software produce?Output: ASPECTS score from 0 to 10, highlighted ASPECTS regions, affected side and regions, voxel heatmap/contribution views, affected voxel volume, and editable clinician-reviewed results delivered through the configured workstation or PACS workflow.
  • What is its most important limitation?Key limitation: The tool is not a primary interpretation, does not provide a mobile diagnostic result, and requires clinician review and editing. The FDA intended population excludes hemorrhagic transformation or hematoma and is tied to adult patients within 24 hours of last known well; the validation scanner scope was limited and later versions or other scanners require confirmation.

Clinical takeaway. Clinical role: Brainomix 360 e-ASPECTS registers adult non-contrast brain CT, segments ASPECTS regions, and provides an editable ASPECTS score with highlighted regions and voxel contribution views to assist trained clinicians evaluating suspected ischemic stroke within 24 hours of last known well.

Evidence takeaway. Evidence from the reviewed source record: K243294 FDA evidence is a regulatory ASPECTS segmentation and reader-assistance validation of Brainomix 360 e-ASPECTS; no independent paper or trial was promoted in this timeboxed review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Brainomix 360 e-ASPECTS registers adult non-contrast brain CT, segments ASPECTS regions, and provides an editable ASPECTS score with highlighted regions and voxel contribution views to assist trained clinicians evaluating suspected ischemic stroke within 24 hours of last known well.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Automated ASPECTS registration, region segmentation, and decision-support visualization for clinician review of suspected ischemic stroke; it is not a primary diagnostic interpretation or mobile diagnostic result.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Adult non-contrast brain CT DICOM images for suspected acute ischemic stroke within 24 hours of last known well; the FDA validation was tied to specified Siemens Somatom Definition scanner configurations.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
ASPECTS score from 0 to 10, highlighted ASPECTS regions, affected side and regions, voxel heatmap/contribution views, affected voxel volume, and editable clinician-reviewed results delivered through the configured workstation or PACS workflow.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Emergency, stroke, radiology, or neurovascular workflow for adult non-contrast head CT within 24 hours of last known well.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Trained clinicians evaluating suspected acute ischemic stroke; the output is assistive, editable, and not a replacement for primary image interpretation or clinical judgment.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The tool is not a primary interpretation, does not provide a mobile diagnostic result, and requires clinician review and editing. The FDA intended population excludes hemorrhagic transformation or hematoma and is tied to adult patients within 24 hours of last known well; the validation scanner scope was limited and later versions or other scanners require confirmation.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K243294 FDA evidence is a regulatory ASPECTS segmentation and reader-assistance validation of Brainomix 360 e-ASPECTS; no independent paper or trial was promoted in this timeboxed review.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K243294 FDA evidence is a regulatory ASPECTS segmentation and reader-assistance validation of Brainomix 360 e-ASPECTS; no independent paper or trial was promoted in this timeboxed review.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
69% (95% CI: 56%, 75%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
97% (95% CI: 80%, 97%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Overall AUC

0.83 area under ROC curve

  • EndpointOverall ASPECTS-related classification performance
  • Population137 non-contrast head CT scans from three U.S. institutions
  • Tested versionBrainomix 360 e-ASPECTS configuration described in K243294

Overall sensitivity

0.69 proportion

  • EndpointSensitivity for the FDA-described ASPECTS endpoint
  • Population137 non-contrast head CT scans from three U.S. institutions
  • Tested versionBrainomix 360 e-ASPECTS configuration described in K243294

Overall specificity

0.97 proportion

  • EndpointSpecificity for the FDA-described ASPECTS endpoint
  • Population137 non-contrast head CT scans from three U.S. institutions
  • Tested versionBrainomix 360 e-ASPECTS configuration described in K243294

MRMC reader AUC with e-ASPECTS

0.85 area under ROC curve

  • EndpointSeven-reader MRMC AUC with e-ASPECTS assistance
  • PopulationMRMC reader study of 140 scans
  • Tested versionBrainomix 360 e-ASPECTS configuration described in K243294

K243294 Brainomix 360 e-ASPECTS regulatory validation

  • DesignRetrospective regulatory validation of ASPECTS registration and segmentation plus a multi-reader multi-case comparison with and without software assistance.
  • PopulationStandalone validation of 137 non-contrast head CT scans from three U.S. institutions; MRMC reader comparison of 140 scans by seven readers.
  • Scopeexact submission
  • Tested versionBrainomix 360 e-ASPECTS configuration described in K243294
  • Samplen=140
  • Sites3
  • IndependenceSponsor or vendor study

K243294

Manufacturer-submitted FDA evidence; the reader comparison is regulatory evidence, not an independent clinical-outcome study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K243294. This does not establish absence of family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult non-contrast brain CT DICOM images for suspected acute ischemic stroke within 24 hours of last known well; the FDA validation was tied to specified Siemens Somatom Definition scanner configurations.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K243294: Brainomix 360 e-ASPECTS

  2. Routing

    Source context, not route validation: The exact submission accepts brain CT DICOM through a standalone server or physical/virtual server, sends results to PACS or its web interface, and can provide compressed previews through configured channels; local DICOM routing, scanner compatibility, PACS behavior, and acknowledgement require acceptance testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K243294: Brainomix 360 e-ASPECTS

  3. AI processing

    Source context, not route validation: The FDA packet describes standalone off-the-shelf physical or virtual server deployment with DICOM transfer to PACS and a web interface; it does not establish current hosting region, retention, availability, service terms, or the installed infrastructure configuration.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K243294: Brainomix 360 e-ASPECTS

  4. Returned objects

    Source context, not route validation: ASPECTS score from 0 to 10, highlighted ASPECTS regions, affected side and regions, voxel heatmap/contribution views, affected voxel volume, and editable clinician-reviewed results delivered through the configured workstation or PACS workflow.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K243294: Brainomix 360 e-ASPECTS

  5. Viewer/worklist/report

    Unresolved route: ASPECTS score from 0 to 10, highlighted ASPECTS regions, affected side and regions, voxel heatmap/contribution views, affected voxel volume, and editable clinician-reviewed results delivered through the configured workstation or PACS workflow.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K243294: Brainomix 360 e-ASPECTS

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA packet describes standalone off-the-shelf physical or virtual server deployment with DICOM transfer to PACS and a web interface; it does not establish current hosting region, retention, availability, service terms, or the installed infrastructure configuration.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The exact submission accepts brain CT DICOM through a standalone server or physical/virtual server, sends results to PACS or its web interface, and can provide compressed previews through configured channels; local DICOM routing, scanner compatibility, PACS behavior, and acknowledgement require acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-07
Security
Brainomix's current official FAQ describes ISO 27001, GDPR, and DPA controls for the current Brainomix 360 family; this does not establish certificate scope, expiry, deployed configuration, or exact K243294 security controls.
  • Product family
  • Checked 2026-09-07

Obtain current certificate scope, data-processing terms, hosting region, encryption, identity/access, audit, retention, and incident-response evidence for the deployed release.

Training
Trained clinicians must review and may edit ASPECTS results; Brainomix's current family FAQ says clinical users receive group training, but exact K243294 training materials and competency evidence were not established.
  • Product family
  • Checked 2026-09-07

Confirm exact release training, local competency, and escalation procedures.

Monitoring
Monitor eligible scanner and CT protocol inputs, registration and ASPECTS edits, discordance with primary reading, result delivery and acknowledgement, downtime, updates, complaints, and recalls by exact K243294 release.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and validation scope; it is not a claimed vendor monitoring service.

DICOM/PACS stroke workflow

Brainomix's current official FAQ describes Brainomix 360 support for major scanner and PACS manufacturers using DICOM, with engineers testing connections before go-live; confirm exact K243294 scanner scope and local interface behavior.

product family · checked 2026-09-07

Current family FAQ; it does not establish every current feature or deployment term for the K243294 release.

Editable result review

The current family FAQ says clinicians can review and edit ASPECTS and that edits are labelled; local acceptance should verify edit provenance, PACS/web delivery, and the distinction between compressed previews and diagnostic source images.

product family · checked 2026-09-07

Current family workflow context; exact K243294 implementation and configuration require confirmation.

Standalone server integration

The exact FDA submission describes physical or virtual server deployment with DICOM transfer and PACS/web result delivery; test scanner eligibility, series routing, processing latency, result acknowledgement, and downtime procedures.

exact submission · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243294
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-02-14
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
26Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or contract unit for the exact K243294 configuration was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Brainomix 360 reimbursement CPT NTAP"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No Brainomix page naming coding or payment for this product was found. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K243294: Brainomix 360 e-ASPECTS

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, training, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Brainomix 360 e-ASPECTS model card (K243294)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Brainomix 360 official FAQ

    Brainomix Limited - Accessed 2026-09-07

    Scope: productFamily, implementationCapabilities, security, training

  8. openFDA exact recall query for K243294

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

Research history

  1. K243294 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K231570

StrokeViewer Perfusion

NICo-Lab B.V.

Authorized purpose: Provide quantitative perfusion information in brain tissue for suspected ischemic stroke patients using dynamic brain CT perfusion studies; medical imaging professionals use the information as additional data in the standard-of-care assessment, not as a standalone diagnostic tool.

Modality
CT/CTA
Anatomy
Brain
Decision
2023-12-14
FDA-cleared K260406

Brainomix 360 Hyperdensity

Brainomix Limited

Authorized purpose: Provides volumetric hyperdensity segmentation and quantification as an aid; physicians must review original images.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-06-12
FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history